The most frequent adverse events ( AEs ) in the telaprevir phase were fatigue ( 47 % ) , pruritus ( 43 % ) , anemia ( 42 % ) , nausea ( 37 % ) , rash ( 35 % ) , and headache ( 26 % ) ; serious AEs were reported in 9 % of patients .